Compare TEF & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEF | WST |
|---|---|---|
| Founded | 1924 | 1923 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 20.2B |
| IPO Year | 1987 | N/A |
| Metric | TEF | WST |
|---|---|---|
| Price | $4.01 | $269.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $346.78 |
| AVG Volume (30 Days) | ★ 1.1M | 674.2K |
| Earning Date | 11-04-2025 | 10-23-2025 |
| Dividend Yield | ★ 5.82% | 0.33% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | N/A | ★ 6.75 |
| Revenue | ★ $48,832,570,697.00 | $3,017,900,000.00 |
| Revenue This Year | N/A | $7.01 |
| Revenue Next Year | $0.09 | $6.20 |
| P/E Ratio | ★ N/A | $39.86 |
| Revenue Growth | 2.59 | ★ 4.92 |
| 52 Week Low | $3.89 | $187.43 |
| 52 Week High | $5.72 | $348.90 |
| Indicator | TEF | WST |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 47.45 |
| Support Level | $3.90 | $264.92 |
| Resistance Level | $4.31 | $275.56 |
| Average True Range (ATR) | 0.06 | 7.59 |
| MACD | 0.01 | -0.62 |
| Stochastic Oscillator | 25.83 | 24.12 |
Telefonica is a telecom operator with presence in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.